P-glycoprotein is an ATP-binding cassette multidrug transporter that actively transports chemically diverse substrates across the lipid bilayer. The precise molecular mechanism underlying transport is not fully understood. Here, we present crystal structures of a eukaryotic P-glycoprotein homolog, CmABCB1 from Cyanidioschyzon merolae, in two forms: unbound at 2.6-Å resolution and bound to a unique allosteric inhibitor at 2.4-Å resolution. The inhibitor clamps the transmembrane helices from the outside, fixing the CmABCB1 structure in an inward-open conformation similar to the unbound structure, confirming that an outward-opening motion is required for ATP hydrolysis cycle. These structures, along with site-directed mutagenesis and transporter activity measurements, reveal the detailed architecture of the transporter, including a gate that opens to extracellular side and two gates that open to intramembranous region and the cytosolic side. We propose that the motion of the nucleotide-binding domain drives those gating apparatuses via two short intracellular helices, IH1 and IH2, and two transmembrane helices, TM2 and TM5. multidrug resistance | ABC transporter | membrane protein | X-ray crystallography | macrocyclic peptide M ultidrug transporters of the ATP-binding cassette (ABC) superfamily, such as P-glycoprotein (P-gp; MDR1; ABCB1), MRP1 (ABCC1), and ABCG2 (BCRP), transport a large number of structurally unrelated compounds with molecular weights ranging up to several thousand Daltons (1, 2). These transporters not only play important roles in normal physiology by protecting tissues from various toxic xenobiotics and endogenous metabolites but also contribute to multidrug resistance (MDR) in tumors, a major obstacle to effective chemotherapeutic treatment (1,(3)(4)(5)(6)(7). Their functional forms consist of a minimum of four core domains: two transmembrane domains (TMDs) that create the translocation pathway for substrates and two nucleotide-binding domains (NBDs) that bind and hydrolyze ATP to power the transport process (8, 9). These four domains can exist either as two separate polypeptides (half-size) or fused together in a single large polypeptide with an internal duplication (full-size). The crystal structures of mouse and nematode P-gps, as well as their bacterial homologs (10)(11)(12)(13)(14), have been determined, and they have provided important insights into the relationships between protein structure and the functional and biochemical characteristics of P-gp. However, the detailed architecture of the TMD machinery and the gating mechanism during the transition between the inward-and outward-open states are poorly understood.
M
ultidrug transporters of the ATP-binding cassette (ABC) superfamily, such as P-glycoprotein (P-gp; MDR1; ABCB1), MRP1 (ABCC1), and ABCG2 (BCRP), transport a large number of structurally unrelated compounds with molecular weights ranging up to several thousand Daltons (1, 2). These transporters not only play important roles in normal physiology by protecting tissues from various toxic xenobiotics and endogenous metabolites but also contribute to multidrug resistance (MDR) in tumors, a major obstacle to effective chemotherapeutic treatment (1, (3) (4) (5) (6) (7) . Their functional forms consist of a minimum of four core domains: two transmembrane domains (TMDs) that create the translocation pathway for substrates and two nucleotide-binding domains (NBDs) that bind and hydrolyze ATP to power the transport process (8, 9) . These four domains can exist either as two separate polypeptides (half-size) or fused together in a single large polypeptide with an internal duplication (full-size). The crystal structures of mouse and nematode P-gps, as well as their bacterial homologs (10) (11) (12) (13) (14) , have been determined, and they have provided important insights into the relationships between protein structure and the functional and biochemical characteristics of P-gp. However, the detailed architecture of the TMD machinery and the gating mechanism during the transition between the inward-and outward-open states are poorly understood.
Here, we report the structures of a eukaryotic P-gp homolog, unlocked (at 2.6-Å resolution) and locked allosterically with a tailor-made peptide at 2.4-Å resolution. Although CmABCB1 is not a full-length ABC transporter but a half-sized ABC transporter adopting a homodimeric architecture, CmABCB1 showed quite similar functional properties to those of human P-gp (hP-gp). Based on these structures, we propose mechanisms by which the intramembranous entrance gate can take up various substrates from the inner leaflet of the membrane bilayer. Although the entrance and exit gates are assembled from distinct transmembrane helices, and their gating motions are in opposite directions, the mechanisms powered by the dimerization motions of the NBDs enable one gate to close while the other gate simultaneously opens with the aid of two short intracellular helices and two transmembrane helices, which act as a lever arm. This mechanism is totally different from that of solute carrier (SLC) transporters (15) (16) (17) (18) (19) and ABC importers (20) , in which the intra-and extracellular gating apparatuses are constructed from the same transmembrane helices. Furthermore, a part of the intramembranous entrance gate has another function gating the pathway from the inside of the transporter to the cytosol. The mode of action of the novel inhibitor, which disables the diverging outward motions of the TM helices by clamping them from the outside of the transporter, supports our proposed gating mechanism.
Results and Discussion Structure Determination. To select a protein for high-resolution structure determination, we searched for ABC transporters closely resembling P-gp in the genome of Cyanidioschyzon merolae (21), a thermophilic unicellular eukaryote. This screen resulted in identification of CMD148C, the protein in the C. merolae genome Significance P-glycoprotein exports various hydrophobic chemicals in an ATP-dependent manner, determines their absorption and distribution in the body, and is involved in multidrug resistance (MDR) in tumors. Understanding the mechanism of the multidrug transport is important for designing drugs of good bioavailability and efficient cancer chemotherapy. We determined the high-resolution crystal structures of a eukaryotic P-glycoprotein homolog and revealed the detailed architecture of its transmembrane domains, which contain an exit gate for substrates that opens to the extracellular side and two entrance gates that open to the intramembranous region and the cytosolic side. We propose a motion of the transmembrane domains powered by the association of two nucleotide-binding domains on ATP binding that is different from other transporters.
whose amino acid sequence, multidrug specificity, and kinetics of ATP hydrolysis are most similar to that of hP-gp (SI Results, Fig. 1 , Figs. S1 and S2, and Table S1 ). On the basis of its similarity to hP-gp, we named this protein CmABCB1 and solved its crystal structure at 2.75-Å resolution by multiwavelength anomalous dispersion (MAD) using a mercury derivative (Tables S2 and S3 ). In the resultant electron-density map, a portion of transmembrane helix 4 (TM4) exhibited very weak density (Fig. S3A) . Therefore, we introduced a triple mutation (G277V/A278V/A279V, hereafter referred to as the GAA/VVV mutant) to reduce the flexibility of the helices; as a result, the resolution was improved to 2.6 Å ( Fig.  S3 B and D and Tables S2 and S3 ). To further enhance crystallization, we introduced a CmABCB1-binding cyclic peptide, aCAP (anti-CmABCB1 peptide), which we identified from an artificial cyclic peptide library containing more than 10 12 unique molecules, using the RaPID system (SI Materials and Methods) (22, 23). The final resolution of the X-ray diffraction was 2.4 Å (Tables S2 and S3 ).
Architecture. The structure of CmABCB1 reveals an overall inwardopen conformation ( Fig. 2A and Fig. S4 ) that is favorable for the uptake of transport substrates. CmABCB1 adopts a homo-dimeric architecture, with each subunit containing an NBD and a cytosolically extruded TMD. The TMD is composed of an N-terminal elbow helix, followed by six α-helices and two short intracellular helices (IH1 between TM2 and TM3, and IH2 between TM4 and TM5). IH1 and IH2 contact the NBD as coupling helices, as shown previously (12) (Fig. 2A) . The homo-dimeric TMD region is formed mainly by tight interactions between TM2 and TM5′ (corresponding to TM2 and TM11 in P-gp) or TM5 and TM2′ (corresponding to TM5 and TM8 in P-gp) via Gly-zipper motifs (G179xxxA183 in TM2, and G344xxxG348 in TM5) that allow the two helices to come into close proximity to form a right-handed helix-helix contact while retaining flexibility (secondary structure elements and amino acid residues belonging to the other subunit are indicated with a prime symbol). The two helices are also connected by interhelical hydrogen bonds near the middle of the outer leaflet and at the polar head group of the inner leaflet of the membrane bilayer. Assembly of this helical pair promotes consolidated movement of the helices at the dimer interfaces and acts as a lever arm for extracellular gating, as we will describe below ( Fig. 2A and Fig. S5 ). On the top of Fig. 1 . CmABCB1 is an ABC multidrug transporter. (A) Dendrogram of ABC transporters from C. merolae and human P-gp (ABCB1). Among 32 ABC proteins from C. merolae, CMD148C is the most similar to human P-gp and was therefore designated as CmABCB1. This dendrogram is based on multiple sequence alignments of the full amino acid sequences of ABC transporters. Alignments were performed using with ClustalW and visualized using Drawtree. CmABCB1, TMs 1, 6, 1′, and 6′ form a right-handed four-helix bundle structure (24) that surrounds the center of the dimer and closes the pathway connecting the inside and outside of the transporter ( Fig. 2A) .
Tailored Macrocyclic Peptide Inhibitor. A tailored cyclic peptide that we identified, aCAP, acts as a surface clamp by binding TM2 and TM6 together from the outer surface of the CmABCB1 dimer, at the interface between the hydrophobic chains and hydrophilic head groups of the outer leaflet of the membrane bilayer ( Fig. 2 A and B) . Lys162 and Tyr163 in TM2 form hydrogen bonds with Gln4 and Trp7 in aCAP, respectively, whereas Asn375 and Asn378 in TM6 form hydrogen bonds with Asn9 and the main-chain carbonyl of Phe8 in aCAP, respectively (Fig. 2B ).
In addition, Phe258 in TM3, and Ile140, Val141, and the alkylchain region of the side-chain of Arg144 in TM1 form van der Waals contacts with Phe8, Ile5, Val6, and Trp7 of aCAP, respectively. Consequently, aCAP clamping can restrain the dynamic movement of the CmABCB1 molecule; and therefore the X-ray diffraction ability of the crystals was improved. However, there is little difference between the crystal structures in the presence and absence of aCAP. aCAP inhibited both the basal and rhodamine 6G-stimulated ATPase activities of CmABCB1. Comparison of the K i for aCAP and K m for rhodamine 6G revealed that aCAP binds CmABCB1 46-fold more tightly than the substrate (Fig. 2C) . K i values for aCAP increased as a function of rhodamine 6G concentration, suggesting that aCAP binding is weakened by helical packing interaction due to rhodamine 6G docking at the interior binding site of the transporter. These results support the notion that dissociation of the helix-bundle interactions specific to the inwardopen conformation is indispensable for transporter function.
Extracellular Gate. Around the aCAP binding region, TM2, TM1, TM6, and TM5 form a linear helix bundle flanked by a fourlayered cluster comprised of interior-facing aromatic and hydrophobic residues such as Phe, Leu, Ile, and Tyr, which contact one another closely by van der Waals and/or hydrophobic interactions (Fig. 3A) . The thickness of this cluster is similar to that of the outer leaflet of the lipid bilayer. The TM1-TM6 interactions in the cluster are also mediated by several hydrogen bonds: Gln147 to Asn375 and NH of Gly377, and the main-chain amide of Gly143 and carbonyl of Ala139 to Thr381 (Fig. 3A) ; these interactions are promoted by the hydrophobic environment created by the four-layered cluster. The linear bundle flanked by the four-layered cluster associates with the corresponding assembly in the other subunit to form the dimer molecule. This architecture stabilizes the inward-open structure, explaining the low basal and high drug-stimulated ATPase activities that are characteristic of P-gps (25-27) and are also observed in CmABCB1 (Fig. 1E) . The bulky side chains in the cluster fill the inner space, preventing entry of extracellular fluid into the spacious internal cavity (WT, 7,648 Å 3 ; GAA/VVV mutant, 6,773 Å 3 ), which has been proposed to be the substrate-binding site (10) located in the inner leaflet of the lipid bilayer.
Functional Residues Lining the Cavity. To identify the residues required for the transport function, we performed Ala substitution of the residues in the cluster. Replacement of several residues markedly decreased transport activity in a drug-susceptibility assay using rhodamine 6G (Fig. S6 A and B) ; these residues, Tyr358, Phe138, Phe384, Ile387, and Leu388, are all located on the ceiling of the cavity (Fig. 3A) . Mutants with Ala substitutions also exhibited reduced affinity for rhodamine 6G, as revealed by kinetic analysis of their ATPase activities ( Fig. S6C and Table  S1 ). Notably, Ala substitution of Tyr358 caused the greatest loss of both transport activity and affinity. Tyr358 is the only residue bearing a side-chain that can act as a hydrogen-bonding acceptor near the ceiling of the cavity. Many substrates for hP-gp contain hydrogen-bonding donor groups, and Tyr358 may form hydrogen bonds with these moieties (28, 29). To explore this possibility, we replaced Tyr358 with Phe or His. In decreasing order, the effective drug resistances bestowed by the mutant CmABCB1s were as follows: WT > Y358H > Y358F > Y358A (Fig. 3B and Fig. S6B) ; this result suggests that the hydroxyl group, as well as the steric portion of the side-chain, is important.
These findings imply that a right-handed four-helix bundle consisting of TM1, TM6, TM1′, and TM6′, in association with two other helices, TM5 and TM5′, forms an extracellular gate through spatial coordination of the aromatic and bulky hydrophobic residues Tyr358 (TM5), Phe138 (TM1), Phe384 (TM6), Ile387 (TM6), and Leu388 (TM6) (Fig. 3C) . Those residues are arranged such that the distances between them are suitable for van der Waals contacts; in particular, Tyr358 on TM5 is closer to Phe138 on TM1′ and Ile387 on TM6 than those residues are to each another and therefore interacts with each of them more strongly. This arrangement suggests that movement of TM5 results in unlocking and elicits dissociation of the tight interactions between TM1 and TM6 in the inward-open state, thereby opening the extracellular gate. The hydrogen bonding of Tyr358 with bulky hydrophobic substrates is expected to perturb the van der Waals interactions between the aromatic and hydrophobic residues listed above and may trigger the opening of the extracellular gate (Fig. 3C ). This extracellular gating mechanism could explain why allosteric inhibition by aCAP is disturbed by substrate binding (Fig. 2C) . The corresponding residues of Tyr358 are highly conserved in human and mouse P-gps (Fig. S1 ), and it is one of the residues that have been proposed to interact with the QZ59 compounds, a family of ATPase modulators, in the internal cavity of mouse P-gp (10).
Intramembranous Gate. A wide cleft between TM4 and TM6 spans the hydrophobic interface between the TMD and the inner leaflet of the putative lipid bilayer ( Fig. 2A) . In the WT structure, the region from Gly277 to Gly286 of TM4 near the amphipathic interface in the inner leaflet of the bilayer is flexible (Fig. 4A) , as reflected by the fact that this region exhibited very weak electron density ( Fig. S3 A and C) . This behavior of the TM4 structure was unchanged by aCAP binding, suggesting that flexibility could be an intrinsic property of the transporter. Most substrates of ABC multidrug transporters are hydrophobic and consequently concentrated in the membrane bilayer (1). To take up such substrates, the entrance gate of the transporter needs to open laterally into the lipophilic interior of the membrane bilayer. The width of the cleft between TM4 and TM6 in the membrane bilayer is not sufficient to allow uptake of larger molecules in such a fashion. However, TM4 is unfolded from Gly277 to Gly286 and kinked at Pro271 and Gly299 ( Fig. 4A and Fig. S3D ), suggesting that because of its flexibility, TM4 enables the entrance gate to open as wide as the distance between TM5 and TM6. This notion is supported by two mutation experiments that we performed on TM4. The GAA/VVV mutant, which restricts TM4 movement ( Fig. S3 B and D and Tables S2 and S3), exhibited significantly reduced drug-transport activity for either rhodamine 6G or smaller molecules, tetraphenylphosphonium bromide and fluconazole ( Fig. 4B and Fig. S3E ), as well as lower basal and substrate-stimulated ATPase activities ( Fig. 4C and Table S1 ). Furthermore, Ala substitution of Pro271, which is a highly conserved residue (Fig. S1 ) and is located around the midpoint of the bilayer, also decreased transport activity ( Fig.  4B and Fig. S3E ). Proline is a key residue for hinge bending motion of TM helices (30). Therefore, P271A mutation also could cause perturbation of dynamic motion of TM4. These results suggest that the flexibility or mobility of the TM4 helix is critical for efficient drug binding and transport. Thus, TM4 is a "gatekeeper" of the substrate entrance gate. Consistent with these findings, TM10 of C. elegans P-gp, which corresponds to TM4 of CmABCB1, is also unstructured (11) . (Fig. S5 ). The tilting of TM2′ by 14°and TM5 by 12° (Fig. 5B ) directly pulls TM1′ and TM6 in the same direction ( Fig S7C) . Thus, the extracellular terminals of TM1 and TM6 move in opposite directions by 11.2 and 7.8 Å, respectively, thereby dissociating TM1 and TM6 from each other ( Inhibition by aCAP, which forms bidentate hydrogen bonds to TM2 and TM6, which tightly sandwich TM1, provides experimental evidence that the TM1-TM6 dissociation is indispensable for the transporter activity. As a consequence of the combination of tilt and rotation as well as translation, the direction of outward-gate opening is approximately perpendicular to that of the translational motion of the NBDs (Fig. 5A and Fig.  S7C ). In the cytosolic region near the NBDs, TMs 3, 4, 3′, and 4′ form another right-handed four-helix bundle structure surrounding the center of the dimer, and this structure closes the pathway from the inside of the transporter to the cytosol ( Fig. 5C and Movie S1). During this motion, TM4 is straightened and interacts with TM3 in the cytosol, drawing TM6 away from TM6′ perpendicular to the translational motion of the NBDs (Fig.  S7D ). This movement of TM6 may also assist in efficient formation of an outward-open state. This perpendicular motion, mediated by the gating mechanisms described above, may permit wide opening of the gates against the lateral pressure exerted by the lipid bilayer.
Transport Mechanism. The transport mechanism of the eukaryote P-gp homolog ABC multidrug transporter, which we revealed in this study, can be summarized as follows. Transport substrates can enter from the inner-leaflet side of the lipid bilayer. Entry of substrate molecules is regulated by the intramembrane gatekeeper, TM4, whose flexibility enables uptake of substrates with various sizes and structures. On the upper side of the TMDs, the extracellular exit gate consists of the right-handed four-helix bundle (TMs 1, 6, 1′, and 6′), along with two other helices, TM5 and TM5′. These structures are locked by the four-layered cluster of hydrophobic and aromatic residues and hydrogen bonds between TM1 and TM6, which together maintain the structure of ABC transporter in the inward-open state. A substrate molecule attaches to the hydrophobic ceiling of the inner cavity and interacts with a Tyr residue (Tyr358 in CmABCB1), which induces the opening of the extracellular exit gate and accelerates ATPase activity. These structural features and processes are consistent with the "vacuum cleaner" model (31, 32). The movement of these TMs in opposite directions is caused mostly by the tilting of the transmitter helices, TM2 and TM5′ or TM2′ and TM5, which is powered by dimerization of the NBDs. The inhibitor aCAP reinforces the TM1-TM6 interaction and thereby prevents the extracellular gate from opening. This unique inhibitory mechanism strongly suggests that opening of the extracellular gate is required for the substrate-dependent ATP hydrolysis cycle of ABC multidrug transporters.
Materials and Methods
For crystallographic experiments, WT CmABCB1 fused to a tobacco etch virus (TEV) protease-cleavable C-terminal His 10 affinity tag was overexpressed in Pichia pastoris SMD1163 cells, whereas mutant CmABCB1 variants with C-terminal FLAG and His 6 affinity tags were overexpressed in Saccharomyces cerevisiae AD1-8u − cells. Recombinant proteins were purified by immobilized metal-ion affinity chromatography (IMAC). The C-terminal His 10 tag of purified WT CmABCB1 protein was then digested by TEV protease, and the cleaved C-terminal His 10 tag and TEV protease were removed by passing the digestion reaction through an IMAC column. The WT CmABCB1 (with the C-terminal His 10 removed) and the IMAC purified mutant CmABCB1 variants were further purified by gel filtration after cleavage of the flexible N-terminal region (1-92) by trypsin treatment (Fig. S8 ). For aCAP-CmABCB1 complex formation, aCAP was mixed with CmABCB1 (2:1 molar ratio). The transporter was concentrated to 10 mg/mL in buffer containing 20 mM Tris·HCl (pH 7.0), 150 mM NaCl, and 0.2% (wt/vol) n-decyl-β-D-maltopyranoside. Crystallization was performed by sitting-drop vapor diffusion at 20°C with a precipitation solution containing 14-16% (wt/vol) polyethylene glycol 2000 monomethyl ether and 100 mM magnesium nitrate. X-ray diffraction data (50-2.4 Å, space group R32) were collected using an MAR225HE detector at beamline BL41XU of SPring-8 and processed using the HKL2000 software suite. The initial phases were derived from multiwavelength anomalous dispersion on a mercury derivative. Each final model was obtained by an iterative process of manual model building and refinement against X-ray diffraction data. Crystallographic data and refinement statistics are shown in Tables S2 and S3 . The functional properties of CmABCB1 mutants were examined using ATPase activity assays of the purified preparations and drug susceptibility assays using the CMD148C transformant of S. cerevisiae AD1-8u − , which is susceptible to cytotoxic drugs due to the disruption of seven endogenous ABC transporters. Details of all experimental procedures are described in SI Materials and Methods. 
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SI Results
To choose a protein for high-resolution structure determination, we screened the genome of Cyanidioschyzon merolae (1), a thermophilic unicellular eukaryote. Our search for the ABC transporter whose amino acid sequence is most similar to that of human P-glycoprotein (hP-gp) resulted in identification of CMD148C (Fig.  1A) , a half-size ABC transporter whose sequence exhibits 41% and 37% identity to the N-terminal and C-terminal halves of hP-gp, respectively (Fig. S1) . We also demonstrated, using a reliable drugsusceptibility assay, that CMD148C functions as a multidrug transporter. Specifically, we expressed CMD148C in Saccharomyces cerevisiae strain AD1-8u − , which is susceptible to cytotoxic drugs due to the disruption of seven endogenous ABC transporters (2) . Yeast strains expressing CMD148C exhibit resistance to many drugs known to be substrates of hP-gp, such as rhodamine 6G, monensin, etoposide, tetraphenylphosphonium, and fluconazole (Fig. 1B) . Paclitaxel and vinblastine are well-known substrates of hP-gp (3, 4), but exert little cytotoxicity against yeast cells; therefore, we confirmed and evaluated resistance to these drugs conferred by CMD148C in a drug-susceptibility assay using HEK293 cells (Fig. 1C and Fig. S2 ).
The similarity between CMD148C and hP-gp was underscored by measurements of the ATPase activity of CMD148C in the presence or absence of various substrates of hP-gp (Fig. 1D) . Most hP-gp substrates stimulated the ATPase activity of purified recombinant CMD148C. The verapamil concentration-dependent ATPase activity exhibited the typical bell-shaped profile observed with hP-gp (5-8) (Fig. 1E) . Because the substrate specificity and kinetic properties of CMD148C are very similar to those of hP-gp, we referred to this protein as CmABCB1. C. merolae is a thermophile; consistent with this, CmABCB1 exhibited much higher thermostability than hP-gp (9) (Fig. S8E) , suggesting its suitability for high-resolution structural analysis.
SI Materials and Methods
Cloning. For high-resolution structure determination of a eukaryote homolog of human P-gp, the C. merolae CMD148C gene (encoding a protein that we named CmABCB1) was cloned by PCR amplification from genomic DNA. For expression of CmABCB1 in S. cerevisiae AD1-8u − (2) cells, the full-length gene was inserted into the multiple cloning site of a pABC3 derivative that includes C-terminal FLAG and His 6 affinity tags (GRDYKDDDDKH 6 ) (10). The resultant plasmid was transformed into AD1-8u − cells. For expression of CmABCB1 in Pichia pastoris SMD1163 cells, the full-length gene fused to a C-terminal tobacco etch virus (TEV) protease cleavage site, and the His 10 affinity tag (GSEN-LYFQGRSH 10 ) was inserted into the multiple cloning site of vector pPICZ-A (Invitrogen Life Technologies). CmABCB1 mutants were generated by site-directed mutagenesis, and sequences were verified before use in transformation of yeasts.
Protein Expression. For crystallization of the WT CmABCB1, large-scale production of the recombinant protein was carried out in P. pastoris SMD1163 by fermentative cultivation. A single colony was used to grow a seed culture overnight at 30°C in 10 mL of yeast extract-peptone-dextrose (YPD) medium with shaking at 240 rpm (BioShaker BR-23FP, TAITEC). The 10-mL seed culture was then inoculated to 1 L of YPD medium, and the culture was grown at 30°C to an OD 600 of 5 in a 5-L baffled flask. After being pelleted at 3,000 × g for 15 min, the cells were resuspended in 100 mL of Glycerol-complex medium [1% yeast extract, 2% (wt/vol) peptone, 1.34% (wt/vol) yeast nitrogen base, 1.6 μM biotin, and 1% (wt/vol) glycerol]. Using this as the inoculum, fermentative cultivation was performed using a BIOFLO310 fermenter (New Brunswick Scientific) at a 4-L scale. The concentration of dissolved oxygen (DO) was maintained at 40% air saturation by automatically controlling agitation speed (300-800 rpm), ventilation (4-20 L/min) with the air/oxygen mixture, and oxygen content (0-100%) of the mixture. The pH of the fermentation was maintained above 5.0 by supplying a 28% (wt/vol) NH 4 OH solution. Polypropylene glycol 2000 was added in 100-μL increments to control excess foaming as necessary. The cells in the fermenter were grown at 30°C in MGY medium for 10 h. On depletion of the initial glycerol, the glycerol-feed phase was initiated by supplying glycerol and continued for 10 h. To exhaust the remaining glycerol completely, glycerol feeding was stopped for 30 min. After a DO spike was observed, the temperature was dropped from 30°C to 25°C, and 8 mL of 100% methanol was added to induce protein expression. Following the 3-h transition phase from glycerol to methanol, the methanol phase was initiated. Cells were harvested 8 h after methanol addition, collected by lowspeed centrifugation (3,000 × g, 15 min), and stored at −80°C.
For crystallization of the GAA/VVV mutant CmABCB1 and functional analysis of the WT and mutants, proteins were expressed in S. cerevisiae AD1-8u − cells (2), because large-scale production of these proteins using P. pastoris was not necessary. A single colony was used to grow a seed culture overnight at 30°C in 10 mL of YPD medium with shaking at 240 rpm (BioShaker BR-23FP, TAITEC). The 10-mL seed culture was then inoculated into 1 L of YPD medium in a 5-L baffled flask and grown to an OD 600 of 0.1; the culture was grown at 25°C with shaking at 240 rpm using an Innova 4330 incubator shaker (New Brunswick Scientific). After 24 h, cells were harvested by low-speed centrifugation (3,000 × g, 15 min) and stored at −80°C.
Protein Purification. Affinity purification of CmABCB1 was conducted using the C-terminal His 6 or His 10 affinity tag. Yeast cells were thawed on ice and disrupted using an EmulsiFlex-C4 (Avestin) at 25,000 psi in a buffer containing 20 mM Tris·HCl (pH 7.0) and 150 mM NaCl. The homogenate was clarified by centrifugation at 1,500 × g for 15 min to remove the unbroken cells and nuclei, and then crude membranes were collected by ultracentrifugation (100,000 × g, 1 h). The membranes were mechanically homogenized and subsequently solubilized for 1 h in binding buffer (20 mM Tris·HCl, pH 7.0, 300 mM NaCl, 20 mM imidazole) containing 1% (wt/vol) C 12 E 9 (Wako). Insoluble material was removed by ultracentrifugation (100,000 × g, 1 h), and immobilized metal-ion affinity chromatography (IMAC) resin (Bio-Rad) was added to the supernatant. After a 3-h incubation, the bound protein was eluted with binding buffer containing 300 mM imidazole.
For crystallization of WT CmABCB1, the affinity-purified protein was subjected to protease treatments before size-exclusion chromatography (SEC). The C-terminal His 10 tag of WT CmABCB1 purified from P. pastoris was cleaved off with His-tagged TEV protease, and both the cleaved C-terminal His 10 tag and TEV protease were removed using an IMAC column. The TEV protease-treated proteins were then subjected to trypsin digestion to remove an additional 92 amino acid residues from the N terminus of CmABCB1; this sequence is not present in other ATP-binding cassette (ABC) transporters, including bacterial ABC exporters (Fig. S1 ). The N-terminal sequence was required for proper expression; however, removing it increased the monodispersity of the protein in SEC (Fig. S8, A and B) , as well as the protein's crystallizability as judged by X-ray diffraction, but had little effect on the ATPase properties of the purified preparation (Fig. S8 , C and D, and Table S1 ). Therefore, we used proteolytically N-terminally truncated CmABCB1 for crystal preparation. The affinity-purified GAA/VVV mutant purified from S. cerevisiae was subjected only to trypsin digestion. The trypsin-treated proteins were further purified on an SEC column equilibrated in a buffer composed of 20 mM Tris·HCl (pH 7.0), 150 mM NaCl, and 0.2% (wt/vol) n-decyl-β-Dmaltopyranoside (βDM; Anatrace), and peak fractions were pooled and concentrated to 10 mg/mL.
In the preparation used for ATPase activity assays, membranes (5 mg/mL protein) were solubilized using 1% (wt/vol) n-dodecyl-β-D-maltopyranoside (βDDM; Anatrace) and purified in 0.05% (wt/vol) βDDM; trypsin and TEV protease treatments were omitted.
Crystallization, Data Collection, and Structure Determination. Cocrystallizations of CmABCB1 with either a newly synthesized verapamil analog (KI-58α) or the tailored cyclic peptide (aCAP, anti-CmABCB1 peptide) were performed by preincubating 0.5 mg/mL CmABCB1 with either 50 μM KI-58α or 10-15 μM aCAP for 16-20 h at 20°C. Addition of KI-58α improved the diffraction resolution of the crystals. However, in the process of interpretation of the resultant electron density map, no clear electron densities derived from KI-58α were observed. The samples were then concentrated to 10 mg/mL using an Amicon Ultra-4 concentrator unit with a molecular cutoff of 50 kDa (Millipore). The sample was mixed with an equal volume of crystallization solution containing 14-16% (wt/vol) polyethylene glycol 2000 MME and 100 mM magnesium nitrate. Crystals were grown at 20°C using the sitting-drop vapor-diffusion method. Crystals (0.2 × 0.2 × 0.2 mm 3 ) were flash-frozen and stored in liquid nitrogen. Mercuryderivative crystals of CmABCB1 were prepared by soaking the native crystals in reservoir solution supplemented with 1 mM ethyl mercury phosphate (EMP). Diffraction data were collected on beamline BL41XU at SPring-8, using an MX225HE detector.
Initial phases for the CmABCB1 structures were determined by the multiwavelength anomalous dispersion method, using a threewavelength data set from a mercury derivative. Model building was performed using the COOT (11) and PHENIX (12) packages. Structural refinement was performed in REFMAC5. The quality of the final model was validated with PROCHECK (13) and MolProbity (14) . Details of the data collection and refinement statistics are summarized in Tables S2 and S3 . Molecular graphics were rendered with PyMOL (15).
Synthesis of N,N,N-Tris[4-(3,4-dimethoxyphenyl)butan-1-yl]amine
(KI-58α). General. NMR spectra were obtained on a JEOL JNM-AL300 spectrometer (300 MHz for High resolution mass spectrometry (HRMS) data was recorded on a JEOL JMS-700 spectrometer. Reagents were used as received from commercial suppliers. Silica gel flash column chromatography was carried out using a Yamazen W-prep 2XY system (Yamazen Corporation) with Hi-Flash columns (silica gel, 40 μm).
3-(3,4-Dimethoxyphenyl)propan-1-ol (4).
To an ethanol solution of sodium ethoxide [prepared from sodium (5.24 g, 228 mmol) and ethanol (250 mL)] was added 3,4-dimethoxybenzaldehyde (1; 25.2 g, 152 mmol) and ethyl diethylphosphonoacetate (40.8 g, 182 mmol), and the mixture was stirred for 1 h at room temperature. Ethanol was removed by evaporation, and water (100 mL) was added to the residue. The aqueous layer was extracted with ethyl acetate (100 mL × 3), and the combined organic layer was washed with brine (100 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo to give ethyl (E)-3-(3,4-dimethoxyphenyl)acrylate (2; 44.1 g) as a pale yellow solid. The crude material (2; 44.1 g) was dissolved in ethanol (100 mL), and to the solution was added 10% (wt/wt) palladium carbon (4.41 g). Hydrogen gas was bubbled into the mixture for 3 h at room temperature. The catalyst was filtered off, and the filtrate was concentrated in vacuo to give ethyl 3-(3,4-dimethoxyphenyl)propanoate (3; 34.8 g) as a pale yellow oil. 1 The crude material (3; 34.8 g) was dissolved in anhydrous tetrahydrofuran (500 mL), and the solution was cooled in an ice bath. To the solution was added lithium aluminum hydride (11.1 g, 292 mmol) in small portions, and the mixture was stirred for 18 h at room temperature. To the reaction mixture was successively added water (11.1 mL) and 10% (wt/vol) aqueous sodium hydroxide solution (11.1 mL), dropwise at 0°C. Additional water (33.3 mL) was added, and the mixture was dried over anhydrous magnesium sulfate. The insoluble materials were filtered off, and the filtrate was concentrated in vacuo to give compound 4 (19.5 g, 66% from 1) as a colorless oil. This product was used without purification. To an ice-cold solution of 3- (3,4-dimethoxyphenyl) propan-1-ol (4; 24.1 g, 123 mmol) and triethylamine (25.9 mL, 186 mmol) in dichloromethane (200 mL) was added methanesulfonyl chloride (10.6 mL, 137 mmol) dropwise, and the mixture was stirred for 1.3 h at room temperature. Water (100 mL) was added to the reaction mixture, and the separated aqueous layer was extracted with dichloromethane (75 mL × 3). The combined organic layer was washed with saturated aqueous sodium hydrogen carbonate solution (75 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo to give 3-(3,4-dimethoxyphenyl)propan-1-yl methanesulfonate (5; 34.0 g) as a red oil. The crude material (5; 34.0 g) was dissolved in anhydrous dimethyl sulfoxide (150 mL), and powdered sodium cyanide (16.1 g, 247 mmol) was added to the solution. After stirring for 13 h at room temperature, saturated aqueous solution of sodium hydrogen carbonate (150 mL) was added to the mixture. The aqueous layer was extracted with toluene (100 mL × 3), and the combined organic layer was washed with brine (100 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane:ethyl acetate = 75:25) to give compound 6 (19.0 g, 75% from 4) as a yellow oil. 1 Hydrogen gas was bubbled into a mixture of 4-(3,4-dimethoxyphenyl)butanenitrile (6; 10.0 g, 48.7 mmol), ethanol (100 mL), concentrated hydrochloric acid (10 mL), and platinum oxide hydrate (200 mg) for 4 d at room temperature. The catalyst was filtered off, and the filtrate was made basic by the addition of 10% (wt/vol) aqueous sodium hydroxide solution. The mixture was concentrated, and water (50 mL) was added to the residue. The aqueous layer was extracted with chloroform (50 mL × 3), and the combined organic layer was washed with 10% (wt/vol) aqueous sodium hydroxide solution (50 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography [ethyl acetate, then chloroform:methanol = 90:10, both solvent systems contained 1% (vol/vol) triethylamine] to give compound 7 (5.58 g, 55%) as a yellow oil. To a solution of 4-(3,4-dimethoxyphenyl)butanenitrile (6; 17.0 g, 82.8 mmol) in anhydrous toluene (150 mL) was added diisobutylaluminum hydride solution (1.0 M in toluene, 99 mL, 99.0 mmol) dropwise at −78°C under argon atmosphere. The reaction mixture was stirred for 1 h at the same temperature, and methanol (30 mL) was added dropwise to the solution. The mixture was allowed to warm up to room temperature, and diethyl ether (150 mL) and 1 N HCl (150 mL) were added. After stirring for 30 min at room temperature, the separated aqueous layer was extracted with diethyl ether (75 mL × 3). The combined organic layer was washed with saturated aqueous sodium hydrogen carbonate solution (75 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo to give compound 8 (16.0 g, 93%) as a yellow oil. This product was used without purification. To a solution of compound 8 (3.58 g, 17.2 mmol) and triethylamine (3.1 mL, 22.2 mmol) in dichloromethane (100 mL) was added compound 7 (5.75 g, 27.5 mmol), and the mixture was stirred for 5 min at room temperature. Sodium triacetoxyborohydride (5.82 g, 27.5 mmol) was added, and the mixture was stirred for 1.7 h at room temperature. Aqueous solution of saturated sodium hydrogen carbonate (100 mL) was added to the reaction mixture, and the separated organic layer was extracted with dichloromethane (50 mL × 3). The combined organic layer was washed with brine (50 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography [chloroform:methanol = 95:5, containing 1% (vol/vol) triethylamine] to give compound 9 (2.40 g, 47%) as a yellow oil. Compound 10 (2.92 g, 42%) was also obtained as a yellow oil. 1 After desalting the mRNA-cyclic peptide conjugates from round 2 and subsequent rounds, nonspecific bead-binding cyclic peptides were removed by incubating the desalted cyclic peptidemRNA conjugates with 200-μg magnetic beads for 30 min at 4°C. The supernatant was subjected to four additional preclearances using 100 μg of magnetic bead at 4°C for 30 min each. For round 6, only 10% of the prepared peptide-mRNA molecules were applied to the CmABCB1 binding step to avoid saturation. The cDNA obtained after round 6 was ligated into the plasmid pGEM-T Easy by TA-cloning. DNA sequences were confirmed by FASMAC Co. Ltd.
The binding abilities of clones #6-1, #6-2, #6-3, and #6-5 (aCAP) were determined using single-clone display. The assay conditions used were the same conditions as the second round of selection. The selected cyclic peptides were chemically synthesized with only a single glycine-carboxamide in place of the (Gly-Ser) 3 linker used in the selection. All cyclic peptides were synthesized using an automated peptide synthesizer (Syro; Biotage) as previously described (16) . Following synthesis, peptides were cleaved from the resin and cyclized. Cyclic peptides were purified using HPLC (Imtakt Cadenza CD-C18 250 × 10-mm column; Gilson HPLC). The mass was verified by MALDI-TOF MS (Autoflex II; Bruker Daltronics). Compound #6-5 exhibited the highest affinity to CmABCB1 in the ATPase inhibition assay, and this is the compound referred to as aCAP (anti-CmABCB1 peptide). − expressing WT or mutant CmABCB1 were precultured in YPD medium at 30°C for 16 h, inoculated in YPD medium to an OD 600 of 0.5, and then cultured at 30°C to an OD 600 of 2-3. These cultures were then diluted in YPD medium to an OD 600 of 0.2, and 50 μL of each cell suspension was inoculated into 450 μL YPD medium containing a drug at the indicated concentration in a 96-well V-shaped MasterBlock (Greiner Bio One). After culture at 30°C for 13-14 h, OD 600 values of the cell suspensions were measured. For each mutant, the assay was performed using four to eight clones, and the averages and SDs of the measured values were calculated. Glu610 is the catalytic residue, corresponding to Glu556 or Glu1201 in hP-gp (18) , and the Ala substitution of the residue abolished the transporter function (Fig. S6A) . The expression levels of mutant proteins were evaluated by Western blot analysis to detect the FLAG tag fused to the C terminus of CmABCB1. Total cellular protein (20 μg) from AD1-8u − cells was separated on an SDS polyacrylamide gel and electroblotted onto a nitrocellulose membrane. Proteins were detected by Western blot analysis using mouse monoclonal anti-FLAG antibody (diluted 1:4,000) or mouse monoclonal anti-GAPDH antibody (diluted 1:4,000). Expression levels of the mutants were approximately equal to that of WT (Fig. S6B) .
Transport Activity Assays and Cellular Localization Analysis in HEK293
Cells. For cell viability assays in mammalian cells, the cDNA encoding CmABCB1 that includes C-terminal FLAG and His 6 affinity tags (GRDYKDDDDKH 6 ) was subcloned into the pIREShyg3 vector. The resultant plasmid was transfected into HEK293 cells, and a population of stably transfected cells was selected by the addition of 0.35 mg/mL hygromycin. To obtain highly expressing cells, cells were further selected in 20 nM vinblastine for 1 wk. Mock-transfected and CmABCB1-expressing HEK293 cells were seeded at a cell density of 1,000 cells per well. Cells were incubated for 3 d after addition of drugs, and cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (19) with slight modifications. In brief, cells were incubated with DMEM containing 0.1 mg/mL MTT for more than 3 h, and the generated formazan dye was dissolved in DMSO and quantified by measuring the absorption at 560 nm. For the calcein-AM transport assay, mock-transfected and CmABCB1-expressing HEK293 cells were incubated with 50 nM of calcein-AM for 30 min in the presence or absence of 50 μM verapamil and cellular accumulation of calcein was estimated by flow cytometry (excitation: 488 nm/emission: 533 nm). Cellular localization was analyzed by immunostaining and confocal microscopy. Cells stably expressing CmABCB1 were fixed with cold methanol. For blocking, fixed cells were incubated with 10% (vol/vol) goat serum in PBS + (PBS containing 0.1 g/L of CaCl 2 and MgCl 2 6H 2 O). Cells were incubated for 1 h with rabbit polyclonal anti-FLAG antibody (SIGMA) diluted 1:1,000 in PBS + containing 10% (vol/vol) goat serum, and then incubated with fluorescent Alexa488-conjugated anti-rabbit IgG (Molecular Probes) for 1 h. Cells were viewed with a 63× PlanNeofluar oil immersion objective using a Zeiss confocal microscope (LSM5 Pascal). No expression of endogenous MDR1 in HEK293/CmABCB1 was confirmed by RT-PCR.
ATPase Measurements. ATPase activity was measured in 50 mM Tris·HCl (pH 7.5), 150 mM NaCl, 0.1 mM EGTA, 0.05% (wt/vol) βDDM, and 10 mM MgCl 2 , with or without ATP and/or compounds, at 37°C. The amount of inorganic phosphate released from ATP was measured using a colorimetric method (20) . The initial hydrolysis rate was calculated by plotting the amount of inorganic phosphate as a function of reaction time.
Determination of Kinetic Parameters for the ATPase Reaction. Four different analyses were performed. For ATP, kinetic parameters were determined using the Michaelis-Menten equation (Eq. S1)
For rhodamine 6G, verapamil, or aCAP, parameters were determined using the following equations (Eqs. S2-S4) (7, 8) :
where v is the initial ATP hydrolysis rate, [e] is the CmABCB1 concentration, [s] is the substrate concentration, k basal is the catalytic rate constant of basal ATPase activity in the absence of drug, k sub is the catalytic rate constant of drug-dependent ATPase activity, K m ATP is the apparent Michaelis constant for ATP in the absence of transport substrates, K m Drug is the Michaelis constant for transport substrates (rhodamine 6G or verapamil) with 5 mM ATP, K i Drug is the inhibition constant for substrate inhibition by transport substrates, and K i is the apparent inhibition constant for rhodamine 6G or aCAP. Fitting was carried out using GRAFIT (Erithacus Software). (Fig. S7A) are indicated by boxes. The alignment was performed using PROMALS3D with manual adjustment. (E) Conserved residues around the interface between IH1, IH2′, and the NBD of CmABCB1. ADP (translucent sticks with magenta carbon) of Sav1866 is superposed onto the NBD of CmABCB1. Conserved residues that form hydrogen bonds between IH1, IH2′, and the NBD, and those that form the nucleotidebinding site, are shown as sticks (yellow carbons). . Thick and thin solid lines are fits of equations to the data, as described in SI Materials and Methods (C, Eq. S2; D, Eq. S1). (E) Thermostability of CmABCB1 ATPase activity. Purified full-length CmABCB1 was preincubated in 20 mM Tris·HCl (pH 7.5), 150 mM NaCl, and 0.05% (wt/vol) βDDM for the indicated times at 42, 48, 52, 55, or 58°C. At the indicated time intervals, aliquots were used for ATPase assays. Residual ATPase activities of the preincubated samples were calculated from the specific ATPase activity, which was determined by subtracting the basal activity from the rhodamine 6G-stimulated activity, expressed as a percentage of the original specific activity. Data are means ± SD (n = 3). ) are excluded from the coordinates. § As defined in MolProbity.
